^
Association details:
| Biomarker: | TISvopra |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | pimivalimab (JTX-4014) (PD1 inhibitor) + vopratelimab (JTX-2011) (ICOS agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
181P - SELECT: A phase 2 randomized trial evaluating 2 doses of vopratelimab (V) + pimivalimab (P) vs P in TISvopra selected patients (pts)
Published date:
12/01/2022
Excerpt:
69 TISvopra positive pts with metastatic NSCLC after 1 prior platinum-containing regimen were randomized 2:1:1 to P 1000 mg (MC1, n=36), P+V 0.1 mg/kg (CC1, n=18) or P+V 0.03 mg/kg (CC2, n=15) q6w….CC2 trended favorably for 1° endpoint, ORR, and PFS. ORR (95% confidence interval [CI]) was 40% (16, 68) for CC2, 25% (12, 42) for MC1, 17% (4, 41) for CC1. 6 month (mo) PFS rate (95% CI) was 80% (50, 93) for CC2, 33% (16, 50) for MC1, 29% for CC1 (10, 52)....P+V 0.03 mg/kg trends toward improved clinical benefit in 1° and 2° endpoints and responses are durable.
Trial ID:
